Litigation Details for Cephalon Inc. v. Sandoz Inc. (D. Del. 2015)

Cephalon Inc. v. Sandoz Inc. (D. Del. 2015)

Docket		Date Filed	2015-02-23
Court	District Court, D. Delaware	Date Terminated	2017-06-29
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	Defendant	Referred To
Patents	8,669,279; 8,883,836; 8,895,756
Link to Docket	External link to docket

Details for Cephalon Inc. v. Sandoz Inc. (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-02-23				External link to document
2015-02-22	6		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,669,279 B2; US 8,883,836 …2015 29 June 2017 1:15-cv-00178 830 Patent Defendant District Court, D. Delaware	External link to document

Litigation summary and analysis for: Cephalon Inc. v. Sandoz Inc. (D. Del. 2015)

Last updated: July 15, 2026

Cephalon Inc. v. Sandoz Inc. (1:15-cv-00178) Litigation Summary: What patents were at issue, what happened procedurally, and what it means for generic entry risk

Cephalon Inc. v. Sandoz Inc., Case No. 1:15-cv-00178, is a federal Hatch-Waxman patent dispute brought by Cephalon against Sandoz tied to ANDA-led generic launch risk for a Cephalon brand drug in the Central Nervous System/controlled-substance segment (Cephalon’s most common Hatch-Waxman targets are for products such as Nuvigil/Provigil family and Ritalin-family/IR-ER ADHD products, and also wakefulness/insomnia agents). The case posture and the typical Hatch-Waxman structure indicate a dispute over one or more Orange Book-listed patents and the generic’s intended FDA approval.

However, the record needed to produce a complete, accurate litigation summary for this specific docket number (including the asserted patent list, dates of key filings, court orders, claim construction, settlement terms, and final judgment or dismissal grounds) is not present in the available input.

What patents were asserted in Cephalon v. Sandoz, and which Orange Book-listed rights were targeted?

A complete “what patents were at issue” summary requires the docket’s pleadings and the final order identifying:

• Asserted U.S. patent numbers and claims (typically listed in the complaint and/or amended complaint)
• Whether the case was limited to specific Orange Book patents (drug substance, drug product, method of use, or formulation)
• Whether the dispute was over Paragraph IV certifications, and which patents were certified as invalid/non-infringed
• Whether Cephalon alleged infringement of one or more specific claim numbers

No such patent-identification details are provided in the user prompt.

Cephalon’s typical patent categories in Hatch-Waxman disputes

In Cephalon ANDA litigations, asserted patents often fall into one or more buckets:

• Formulation patents for extended-release or abuse-deterrent-type product characteristics
• Method-of-use patents for labeled dosing regimens
• Manufacturing/process patents related to controlled release performance
• Polymorph/drug substance patents, where applicable

A category-level description cannot be mapped to this docket without the case filings.

When did the case start, and what was the procedural timeline (complaint, answer, claim construction, trial, dismissal)?

A litigation timeline must cite docket milestones such as:

• Complaint filing date (and jurisdiction details)
• Answer and any counterclaims
• Claim construction schedule and Markman dates
• Motions to dismiss, summary judgment, preliminary injunction, or stay
• Any settlement dates and entry of consent judgment
• Final disposition (dismissal with/without prejudice, judgment on the merits, or termination after settlement)

The docket number alone is insufficient to reconstruct those events accurately.

Was this case stayed under 35 U.S.C. § 271(e)(4) or adjudicated on the merits?

Hatch-Waxman cases frequently involve:

• An automatic or court-ordered procedural stay tied to ANDA exclusivity and patent litigation timing
• Settlement-driven termination
• Merits adjudication on infringement/invalidity
• Dismissal for non-justiciability or covenant/non-infringement positioning

No disposition or stay information is included in the provided input.

What did the court rule on infringement and invalidity?

A true litigation analysis requires the substance of court rulings:

• Infringement findings for each asserted claim
• Validity outcomes (anticipation, obviousness, enablement, indefiniteness, written description)
• Claim construction determinations that control infringement analysis
• Any injunction, licensing/consent-to-launch terms, or “design-around” findings

No order text, claim construction record, or judgment summary is provided.

Did Cephalon and Sandoz settle, and what settlement terms drove market entry timing?

A settlement summary normally covers:

• Whether Sandoz agreed to a launch date or entered an interim supply agreement
• Whether a “generic launch-at-risk” occurred after settlement
• Any payment structure (where publicly disclosed)
• Any covenant not to sue scope and carve-outs
• Alignment with Patent Term Adjustments (PTA) or pediatric exclusivity, where relevant

The prompt provides no settlement documentation.

What is the Orange Book status of the relevant Cephalon drug and patents at issue in this docket?

Orange Book status analysis requires:

• Drug product listing and NDA/ANDA numbers
• Patent list for the NDA (including expiration dates and exclusivity codes)
• Whether the listed patents correspond to those asserted in the complaint
• Any FDA “30/180-day exclusivity” triggers tied to the ANDA filer

No NDA/ANDA or Orange Book mapping is provided.

How strong was Cephalon’s patent estate based on this litigation posture and outcomes?

“Patent strength” analysis depends on objective litigation outcomes:

• Win/loss on infringement or invalidity
• Surviving asserted claims after motions
• Claim construction results that narrow or broaden Cephalon’s scope
• Court skepticism signals (e.g., indefiniteness, lack of written description)
• Any appellate activity

Without docket orders and outcomes, strength cannot be quantified.

What generic entry risks exist for Sandoz or other ANDA filers after this case?

Generic entry risk assessment needs:

• Whether Sandoz obtained design-arounds or non-infringement rulings
• Whether Cephalon’s patents were invalidated or narrowed
• Whether any residual patents (not asserted in the case) remain in the Orange Book
• Whether FDA approval was blocked by 271(e)(8) injunctions
• Whether other Paragraph IV litigations exist on the same NDA

None of these specifics are available in the prompt.

Which other companies litigated similar patents against Cephalon around the same time, and how did that affect this case?

Cross-litigations often reveal shared factual issues:

• Same ANDA “skinny label” or “section viii carve-outs”
• Same controlled-release/formulation infringement theory
• Same polymorph/formulation performance metrics
• Same claim construction outcomes in coordinated or repeating cases

No related-case list is provided.

Key Case-Law and Docket Items Table (what should be in the record, but is not provided here)

Field	Required for analysis	Cephalon v. Sandoz (1:15-cv-00178)
Court and division	District, judge, venue	Not supplied
Complaint date	Starts limitations and timeline	Not supplied
Asserted patents	Patent numbers and claims	Not supplied
ANDA/NDA linkage	Which drug product is tied	Not supplied
Paragraph IV details	Which patents were certified & why	Not supplied
Key orders	MTD/claim construction/summary judgment/trial	Not supplied
Disposition	Settlement, dismissal, final judgment	Not supplied
Launch timing impact	Entry date or injunction terms	Not supplied

Key Takeaways

• A litigation summary for Cephalon Inc. v. Sandoz Inc., 1:15-cv-00178 requires docket-specific facts (asserted patent list, Orange Book mapping, procedural milestones, and final disposition).
• The user-provided input does not include those docket records, so a complete and accurate litigation analysis cannot be produced from the available information.

FAQs

1. What is a Paragraph IV patent challenge and how does it drive FDA approval timing?
2. How do claim constructions typically affect infringement analysis in Hatch-Waxman cases?
3. What settlement structures commonly appear in ANDA patent litigations involving extended-release formulations?
4. How do PTA and pediatric exclusivity change the effective “patent life” for generic launch planning?
5. What procedural events most often end a Hatch-Waxman case before trial?

References

1. (No sources were provided in the prompt.)